Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Three cancer drugs approved for NHS use in Scotland November 11, 2021 The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to... June 12, 2019 Load more HOT NEWS EMA Recommends Additional Extensions of Indications for Pembrolizumab A new target to slow down ageing and reduce blood cancer... Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell... Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event...
